RBC Capital Maintains Sector Perform Rating and $22 PT on Valent Pharmaceuticals (VRX) Following Q4 Results, 2017 'Guidance Lower than Street'
Tweet Send to a Friend
RBC Capital Markets analyst Douglas Miehm reiterates Sector Perform rating and $22 price target on Valeant Pharmaceuticals, as the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
